Europe Suspends Sanofi-Aventis Vaccine On Efficacy Concern

LONDON, Sept 20 (Reuters) - The European Medicines Agency has suspended sales of Sanofi-Aventis SA’s (SASY.PA: Quote, Profile, Research) vaccine Hexavac because of concerns it may not offer adequate protection, the drugs watchdog said on Tuesday.